Quantcast

Latest Tapentadol Stories

b73785a5450a63b90b80866b5fe67e911
2011-02-17 06:20:00

Scientists studying the benefits of pain medications said Wednesday that people who do not believe their pain drugs will work may actually reduce or even rescind the effectiveness of those drugs. Researchers from Britain and Germany used brain scans to examine how a person's feelings and past experiences can influence how medicines work in their bodies, and discovered that a powerful painkilling medication with a true biological effect can appear not to be working if a patient has been...

2011-02-15 15:07:00

NASHVILLE, Tenn., Feb. 15, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data from a clinical trial evaluating the pharmacokinetics, safety and tolerability of a rapid infusion of Caldolor® (ibuprofen) Injection compared to oral ibuprofen. The study, which was published in the January issue of American Journal of Health-System Pharmacy, demonstrated that the maximum plasma concentration (Cmax) of IV ibuprofen when...

2011-01-28 07:30:00

RARITAN, N.J., Jan. 28, 2011 /PRNewswire/ -- New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication. This phase III study, which evaluates the safety and efficacy of tapentadol ER against placebo for relieving moderate to severe chronic pain associated with diabetic peripheral neuropathy (DPN), is...

2011-01-27 05:45:00

NASHVILLE, Tenn., Jan. 27, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in the peer-reviewed journal Pain Practice concluded that IV ibuprofen significantly reduced both morphine use and self-reported pain intensity in patients recovering from abdominal...

2011-01-25 00:02:25

Study Designed to Evaluate Side Effect and Safety Advantages of MoxDuo IR Compared to Equi-Analgesic Doses of Morphine and of Oxycodone Sydney, Australia and Bedminster, NJ (Vocus/PRWEB) January 24, 2011 QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of a Phase 3 trial (Study 022) to compare the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone given alone. Specifically, the study compares the incidence level of...

2011-01-20 10:40:00

STAMFORD, Conn., Jan. 20, 2011 /PRNewswire/ -- Butrans(TM) (buprenorphine) Transdermal System CIII from Purdue Pharma L.P. is now available by prescription and indicated for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is the first opioid analgesic that delivers continuous release of buprenorphine for seven days. To view the multimedia assets associated...

2011-01-04 07:00:00

LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B. CVBT's Phase II data indicates that CVBT's FGF-1 biological drug appears to be delivering efficacy at a level significantly greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds. The results of the two...

2010-11-07 16:00:00

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean...

2010-11-04 17:25:00

Indications include osteoarthritis, chronic lower back pain SILVER SPRING, Md., Nov. 4, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo:...

2010-10-17 13:00:00

SAN CARLOS, Calif., Oct. 17 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine. These data were presented during the poster session entitled "Chronic and Cancer Pain" held today at the American Society of Anesthesiologists (ASA 2010) Annual Meeting on October 17, 2010 in...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related